Withdrawn
Tyrosine Kinase Inhibitors, Immune Checkpoint Inhibitors and Everolimus for treating advanced renal cell cancer
Condition
Cancer
Kidney
2 January 2024
Published on 04 Jan 2022
Last Updated on 02 Jan 2024
Tyrosine Kinase inhibitors, Immune Checkpoint inhibitors and Everolimus for treating advanced renal cell cancer Guidance is outdated and has been withdrawn on 31 Aug 2022.
Please refer to the updated recommendations on Update of MOH List of Subsidised Drugs to include treatments for various cancer conditions here.
The Plain English Summary (PES) has been updated on 31 August 2022.
PES Treatments for advanced renal cell carcinoma (Updated 2 Jan 2024) [PDF, 226 KB]